His team harnesses advanced computational technologies, including AI, with the aim of enhancing the discovery, design, optimization and synthesis of small molecules to be developed into innovative ...
Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and ...